"Genentech’s fosters cutting-edge science and encourages innovation. It has been a great privilege to be part of this culture."
I joined Genentech in 2012 as a project toxicologist having worked in the Biotech industry for 5 years. When I arrived I was most impressed with Genentech’s culture that fosters cutting-edge science and encourages innovation. Additionally as scientist we are allowed a great deal of freedom here and it has been an honor to be part of this.
As a project toxicologist on cross functional teams, I provide scientific leadership, evaluate safety liabilities, proactively manage safety liabilities by designing strategies and studies, provide input on issues arising during manufacturing process, and support regulatory filings.
Toxicol Sci. 2016 Jul;152(1):72-84.
In addition to my role as a project toxicologist, I also spearhead the efforts to identify, address and streamline gaps and issues in large molecule immunology discovery portfolio and optimize antibody targets by working with antibody engineer, manufacturing, research, pharmacokinetics and pharmacodynamics colleagues.
My research interest includes identifying novel liver injury biomarkers that has the potential to be more sensitive than ALT and AST. As part of this effort we are evaluating miR-122 in our preclinical studies and clinical trials. Our goal is to understand the utility and translation of this liver safety biomarker from the preclinical to clinical space as well as feasibility and ease of use in a clinical setting.